Apellis Pharmaceuticals, Inc. (APLS) is a Biotechnology company in the Healthcare sector, currently trading at $40.85. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 1 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of APLS = $37.40 (-8.4% from the current price, the stock appears fairly valued). Analyst consensus target is APLS = $34 (-18% upside).
Valuation: APLS trades at a trailing Price-to-Earnings (P/E) of 229.3 (S&P 500 average ~25).
Financials: revenue is $1.0B, +183.8%/yr average growth. Net income is $22M, growing at +64.3%/yr. Net profit margin is 2.2% (thin). Gross margin is 89.8% (-2.7 pp trend).
Balance sheet: total debt is $486M against $370M equity (Debt-to-Equity (D/E) ratio 1.31, moderate). Current ratio is 3.14 (strong liquidity). Debt-to-assets is 45.2%. Total assets: $1.1B.
Analyst outlook: 18 / 25 analysts rate APLS as buy (72%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 18/100 (Fail), Growth 100/100 (Pass), Past 25/100 (Fail), Health 50/100 (Partial), Moat 65/100 (Partial), Future 49/100 (Partial), Income 30/100 (Fail).
